E-POSTER PROGRAMME
SATURDAY
18
SEPTEMBER
Chairs: S. Lacroix-Desmazes (France)
17:15
PO 02 FACTOR VIII INHIBITORS
Selection of immuno-dominant T cell epitopes from the repertoire of FVIII derived peptides presented on MHC class II
M. Miranda (The Netherlands)
17:25
PO 03 FACTOR VIII INHIBITORS
The IgG-degrading enzyme from Streptococcus pyogenes as a new tool for the elimination of factor VIII inhibitors
M. Bou Jaoudeh (France)
17:35
PO 04 FACTOR VIII INHIBITORS
Might prothrombin 543R L a major determinant of mexican american coagulation potential contribute to the disparately elevated factor VIII inhibitor risk in hispanic hemophilia A patients?
T. Howard (USA)
17:45
PO 05 HAEMOPHILIA
Preclinical efficacy and safety assessment of a recombinant factor IX variant that functions independently of factor VIII in combination with current hemophilia A therapeutics
V. Strijbis (The Netherlands)
17:55
PO 16 PUPS
A post-hoc analysis of temporarily decreased incremental recovery observed in a subset of previously untreated patients with haemophilia A treated with N8-GP
C. Male (Austria)
Chairs: C. Denis (France)
17:15
PO 07 HAEMOPHILIA
Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic guided dosing of replacement therapy in hemophilia A?
C. Van Kwawegen (The Netherlands)
17:25
PO 08 HAEMOPHILIA
Confirmed safety profile of BAY 94-9027 prophylaxis for ≥5 years: outcomes from the PROTECT VIII and PROTECT VIII Kids extension studies
M. E. Mancuso (Italy)
17:35
PO 12 NON-REPLACEMENT THERAPIES
Safety of FEIBA and emicizumab (SAFE): dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in hemophilia A patients on emicizumab
H. Kizilocak (USA)
17:45
PO 13 NON-REPLACEMENT THERAPIES
A patient with FVIII inhibitors on emicizumab prophylaxis switching to immune tolerance induction laboratory issues
D. Coen Herak (Hungary)
17:55
PO 14 NON-REPLACEMENT THERAPIES
Emicizumab for the management of children with aevere hemophilia A: experience from hemophilia centres in Lithuania
S. Saluyte Trakymiene (Lituania)
18:05
PO 20 RARE COAGULATION DISORDERS
Catridecacog in the treatment of an Italian population of patients with FXIII deficiency from pharmacokinetics to clinical outcomes (the Italian rFXIII study)
S. Pasca (Italy)
Chairs: J. Voorberg (The Netherlands)
17:15
PO 01 COVID-19
Prothrombotic alterations of von Willebrand factor level and ADAMTS13 activity in hospitalized COVID-19 patients
G. Sinkovits (Hungary)
17:25
PO 15 PUPS
IgG2 as hallmark of inhibitor persistence in PUPs: a longitudinal analysis along exposure to FVIII
S. Miri (Italy)
17:35
PO 06 HAEMOPHILIA
The safety and efficacy of N8-GP in previously untreated patients with severe haemophilia A: interim results from the main and extension phases of Pathfinder6
C. Male (Austria)
17:45
PO 17 PUPS
Inhibitor development upon switch from plasma derived to recombinant FVIII in PUPs with severe haemophilia A: preliminary analysis of the PUP SWITCH study
S. Miri (Italy)
17:55
PO 18 PUPS
The German Pediatric Hemophilia Research Database - the PUP cohort of the "Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis research": a progress report
C. Königs (Germany)
18:05
PO 19 PUPS
Real-world experience with emicizumab in an italian paediatric cohort: focus on PUPs and tolerized children
B. Pollio (Italy)